CN108601751A - 雷公藤红素的类似物 - Google Patents
雷公藤红素的类似物 Download PDFInfo
- Publication number
- CN108601751A CN108601751A CN201680076127.9A CN201680076127A CN108601751A CN 108601751 A CN108601751 A CN 108601751A CN 201680076127 A CN201680076127 A CN 201680076127A CN 108601751 A CN108601751 A CN 108601751A
- Authority
- CN
- China
- Prior art keywords
- mmol
- administration
- solution
- obesity
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C[C@@](CC[C@](CC*)C1)(CC2)[C@]1(C)[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O Chemical compound C[C@@](CC[C@](CC*)C1)(CC2)[C@]1(C)[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O 0.000 description 16
- OENVHBDUFPTPFN-UHFFFAOYSA-N CC(C)=CCC(F)(F)F Chemical compound CC(C)=CCC(F)(F)F OENVHBDUFPTPFN-UHFFFAOYSA-N 0.000 description 1
- KHKKGYYBCRPTCR-HOVVCAQBSA-N CC(C)C(N[C@](C)(CC1)CC(C2CC[C@@]3(C)/C=C/C4=O)[C@@]1(C)CC[C@]2(C)/C3=C/C=C/C(/C)=C4/O)=O Chemical compound CC(C)C(N[C@](C)(CC1)CC(C2CC[C@@]3(C)/C=C/C4=O)[C@@]1(C)CC[C@]2(C)/C3=C/C=C/C(/C)=C4/O)=O KHKKGYYBCRPTCR-HOVVCAQBSA-N 0.000 description 1
- VNQBIUMUTVOJBQ-GPJJGCQNSA-N CC(C)C(N[C@](C)(CCC1(C)CC2)C[C@H]1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(/C(/C)=C/O)/C3=C\C=O)=O Chemical compound CC(C)C(N[C@](C)(CCC1(C)CC2)C[C@H]1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(/C(/C)=C/O)/C3=C\C=O)=O VNQBIUMUTVOJBQ-GPJJGCQNSA-N 0.000 description 1
- AIJBBEAPOZAKLB-CNINVHOZSA-N CC(C)SC(C=C(CC[C@@H]1CC2)[C@]3(C)[C@]2(C)[C@H](C[C@@](C)(CC2)C(N)=O)[C@@]2(C)CC3)c(c(C)c2OC(C)=O)c1cc2OC(C)=O Chemical compound CC(C)SC(C=C(CC[C@@H]1CC2)[C@]3(C)[C@]2(C)[C@H](C[C@@](C)(CC2)C(N)=O)[C@@]2(C)CC3)c(c(C)c2OC(C)=O)c1cc2OC(C)=O AIJBBEAPOZAKLB-CNINVHOZSA-N 0.000 description 1
- HPIFWVFTPJZGSI-UHFFFAOYSA-N CC(C)SC(c1ccccc1)=O Chemical compound CC(C)SC(c1ccccc1)=O HPIFWVFTPJZGSI-UHFFFAOYSA-N 0.000 description 1
- HPZIGUXQWMHSPN-IJUIMPLNSA-N CC(C=C1[C@@]2(C)CC[C@@]3(C)[C@H](C[C@@](C)(CC4)C(OC)=O)[C@@]4(C)CC[C@@H]1C3)c(c(C)c1O)c2cc1O Chemical compound CC(C=C1[C@@]2(C)CC[C@@]3(C)[C@H](C[C@@](C)(CC4)C(OC)=O)[C@@]4(C)CC[C@@H]1C3)c(c(C)c1O)c2cc1O HPZIGUXQWMHSPN-IJUIMPLNSA-N 0.000 description 1
- RSVDGUAMRWSJDI-KYYWSHRGSA-N CC(CC[C@](C)(C1)C(N)=O)(CC2)[C@]1(C)[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1OC)C3=CC1=O Chemical compound CC(CC[C@](C)(C1)C(N)=O)(CC2)[C@]1(C)[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1OC)C3=CC1=O RSVDGUAMRWSJDI-KYYWSHRGSA-N 0.000 description 1
- SUWRJTBAPUFCCQ-DNQIJJMMSA-N CC(C[C@](C)(CC1)[C@@H](C2)[C@](C)(CC[C@]34C)[C@@]1(C)C3=CC=C(C(C)=C1O)C4=CC1=O)C2N(C)C Chemical compound CC(C[C@](C)(CC1)[C@@H](C2)[C@](C)(CC[C@]34C)[C@@]1(C)C3=CC=C(C(C)=C1O)C4=CC1=O)C2N(C)C SUWRJTBAPUFCCQ-DNQIJJMMSA-N 0.000 description 1
- RLFGTOOUIPVTOS-UHFFFAOYSA-N CC(N1CCC(C)CC1)O Chemical compound CC(N1CCC(C)CC1)O RLFGTOOUIPVTOS-UHFFFAOYSA-N 0.000 description 1
- JXSUJBXSKZGCNH-UHFFFAOYSA-N CC(O)ON(CCC1)C1=O Chemical compound CC(O)ON(CCC1)C1=O JXSUJBXSKZGCNH-UHFFFAOYSA-N 0.000 description 1
- CDDHRXNRAWZSAZ-MBWFPREASA-N CCC(N[C@](C)(CC[C@]1(C)CC2)CC1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O)=O Chemical compound CCC(N[C@](C)(CC[C@]1(C)CC2)CC1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O)=O CDDHRXNRAWZSAZ-MBWFPREASA-N 0.000 description 1
- WCKMZQZTBAYBAJ-JEUKPKIZSA-N CCCC[C@@](C)([C@@](C)(CC[C@@]1(C)c(cc2OC(OCC)=O)c3c(C)c2OC(OCC)=O)[C@@H](CCC2)CC[C@H]2C(N)=O)C1=CC3SC(C)C Chemical compound CCCC[C@@](C)([C@@](C)(CC[C@@]1(C)c(cc2OC(OCC)=O)c3c(C)c2OC(OCC)=O)[C@@H](CCC2)CC[C@H]2C(N)=O)C1=CC3SC(C)C WCKMZQZTBAYBAJ-JEUKPKIZSA-N 0.000 description 1
- SZZMMKGXYKHGKN-UHFFFAOYSA-N CCCN1CCOCCC1 Chemical compound CCCN1CCOCCC1 SZZMMKGXYKHGKN-UHFFFAOYSA-N 0.000 description 1
- DRBNQAWOXBAPOC-UHFFFAOYSA-N CCN1CCN(CC)CCC1 Chemical compound CCN1CCN(CC)CCC1 DRBNQAWOXBAPOC-UHFFFAOYSA-N 0.000 description 1
- ROPPLSSCVJALEF-BMMNFCMRSA-N C[C@@](CCC(C)(C1)N(C)C)(CC2)[C@@H]1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O Chemical compound C[C@@](CCC(C)(C1)N(C)C)(CC2)[C@@H]1[C@](C)(CC[C@]13C)[C@@]2(C)C1=CC=C(C(C)=C1O)C3=CC1=O ROPPLSSCVJALEF-BMMNFCMRSA-N 0.000 description 1
- SNVBOOLBULGABE-PUTYEYRUSA-N C[C@@](CC[C@](C)(C1)C(O)=O)(CC2)C1[C@](C)(CC[C@@]1(C)c(c3c4C)cc(OC(C)=O)c4OC(C)=O)[C@@]2(C)C1=CC3SCCOC(C)=O Chemical compound C[C@@](CC[C@](C)(C1)C(O)=O)(CC2)C1[C@](C)(CC[C@@]1(C)c(c3c4C)cc(OC(C)=O)c4OC(C)=O)[C@@]2(C)C1=CC3SCCOC(C)=O SNVBOOLBULGABE-PUTYEYRUSA-N 0.000 description 1
- WCDFYUNYTICGNU-MPXNBLPNSA-N C[C@@](CC[C@](C)(C1)N(C)C(C)=O)(CC2)C1[C@](C)(CC1)[C@@]2(C)C2[C@]1(C)C1=CC3OC3C(O)=C(C)C1=CC2 Chemical compound C[C@@](CC[C@](C)(C1)N(C)C(C)=O)(CC2)C1[C@](C)(CC1)[C@@]2(C)C2[C@]1(C)C1=CC3OC3C(O)=C(C)C1=CC2 WCDFYUNYTICGNU-MPXNBLPNSA-N 0.000 description 1
- DMDJJWIPFKMRRO-SVAVSJLESA-N C[C@@](CC[C@]1(C)CC([C@@]2(C)CCC3(C)C)=CCC(C(C)=C4C)C2=CC4=C)(C[C@]13[I]=C)C(N)=O Chemical compound C[C@@](CC[C@]1(C)CC([C@@]2(C)CCC3(C)C)=CCC(C(C)=C4C)C2=CC4=C)(C[C@]13[I]=C)C(N)=O DMDJJWIPFKMRRO-SVAVSJLESA-N 0.000 description 1
- USZWMUIRGFCAQK-MWVPMHEFSA-N C[C@H](C1)C(CS(N)(=O)=O)C[C@](C)(CC2)[C@@H]1[C@](C)(CC[C@]13C)C[C@@H]2C1=CC=C(C(C)=C1O)C3=CC1=O Chemical compound C[C@H](C1)C(CS(N)(=O)=O)C[C@](C)(CC2)[C@@H]1[C@](C)(CC[C@]13C)C[C@@H]2C1=CC=C(C(C)=C1O)C3=CC1=O USZWMUIRGFCAQK-MWVPMHEFSA-N 0.000 description 1
- BEBIZIZPAIDLKO-QSCLWWSOSA-N C[C@](CC1)(CC[C@](C)(CC2)C(N)=O)[C@H]2[C@](C)(CC[C@]23C)[C@@]1(C)C2=CC=C(C(C)=C1O)C3=CC1=O Chemical compound C[C@](CC1)(CC[C@](C)(CC2)C(N)=O)[C@H]2[C@](C)(CC[C@]23C)[C@@]1(C)C2=CC=C(C(C)=C1O)C3=CC1=O BEBIZIZPAIDLKO-QSCLWWSOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Liquid Crystal (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Optical Filters (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411356905.2A CN119241632A (zh) | 2015-10-23 | 2016-10-21 | 雷公藤红素的类似物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245356P | 2015-10-23 | 2015-10-23 | |
| US62/245,356 | 2015-10-23 | ||
| PCT/US2016/058313 WO2017070615A1 (en) | 2015-10-23 | 2016-10-21 | Analogs of celastrol |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411356905.2A Division CN119241632A (zh) | 2015-10-23 | 2016-10-21 | 雷公藤红素的类似物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108601751A true CN108601751A (zh) | 2018-09-28 |
Family
ID=58558149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411356905.2A Pending CN119241632A (zh) | 2015-10-23 | 2016-10-21 | 雷公藤红素的类似物 |
| CN201680076127.9A Pending CN108601751A (zh) | 2015-10-23 | 2016-10-21 | 雷公藤红素的类似物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411356905.2A Pending CN119241632A (zh) | 2015-10-23 | 2016-10-21 | 雷公藤红素的类似物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10662218B2 (enExample) |
| EP (1) | EP3364956A4 (enExample) |
| JP (3) | JP7034078B2 (enExample) |
| CN (2) | CN119241632A (enExample) |
| AU (3) | AU2016342375B2 (enExample) |
| BR (1) | BR112018008103A2 (enExample) |
| MA (1) | MA45430A (enExample) |
| WO (1) | WO2017070615A1 (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109705187A (zh) * | 2019-01-29 | 2019-05-03 | 石家庄学院 | 一种雷公藤红素衍生物及其制备方法与应用 |
| CN111202737A (zh) * | 2020-03-20 | 2020-05-29 | 中国药科大学 | 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用 |
| CN112094313A (zh) * | 2019-06-17 | 2020-12-18 | 中国科学院上海药物研究所 | 一类氨基取代的雷公藤红素衍生物以及其制备方法和用途 |
| CN112110977A (zh) * | 2019-06-21 | 2020-12-22 | 中国科学院上海药物研究所 | 一类雷公藤红素衍生物、其制备方法及用途 |
| CN115677812A (zh) * | 2022-01-18 | 2023-02-03 | 聊城大学 | 一类雷公藤红素衍生物及其制备方法与应用 |
| CN119431489A (zh) * | 2024-11-13 | 2025-02-14 | 肇源县总医院 | 一种雷公藤红素衍生物及其制备方法 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45430A (fr) | 2015-10-23 | 2019-05-01 | Erx Pharmaceuticals Inc | Analogues de célastrol |
| ES2936226T3 (es) | 2016-04-15 | 2023-03-15 | Beckman Coulter Inc | Macromoléculas fotoactivas y usos de las mismas |
| CN109803664A (zh) * | 2016-06-15 | 2019-05-24 | 尚特·德扎尔基西安 | 用于改善细胞、组织和器官的活力和功能的试剂、组合物和方法 |
| WO2018006804A1 (zh) * | 2016-07-04 | 2018-01-11 | 厦门大学 | 孤儿核受体Nur77的配体及其用途 |
| EP4090658A4 (en) | 2020-01-15 | 2024-03-13 | University Of Florida Research Foundation, Incorporated | THERAPEUTIC AGENTS AND METHODS OF TREATMENT |
| US20230330237A1 (en) * | 2020-08-28 | 2023-10-19 | University Of Florida Research Foundation, Incorporated | Modulators of nuclear receptor subfamily 4 group a member 1 (nr4a1) and uses thereof |
| US20250375401A1 (en) * | 2022-06-21 | 2025-12-11 | Seoul National University R&Db Foundation | Pharmaceutical composition containing demethylzeylasteral for prevention or treatment of diseases caused by muscle loss |
| AU2023306990A1 (en) * | 2022-07-15 | 2025-01-09 | Celloram Inc. | Celastrol derivatives |
| WO2024108024A1 (en) * | 2022-11-17 | 2024-05-23 | Erx Pharmaceuticals, Inc. | Celastrol salts, crystalline forms, and uses thereof |
| EP4618964A1 (en) * | 2022-11-17 | 2025-09-24 | ERX Pharmaceuticals Inc. | Compositions and methods for treatment of prader-willi syndrome |
| WO2025106760A1 (en) * | 2023-11-16 | 2025-05-22 | Erx Pharmaceuticals Corporation | Intranasal formulations of celastrol |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007117466A2 (en) * | 2006-03-31 | 2007-10-18 | Massachusetts Institute Of Technology | Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors |
| US20100240581A1 (en) * | 2006-11-13 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | Selective proteasome inhibitors for treating diabetes |
| US20110166216A1 (en) * | 2007-08-17 | 2011-07-07 | Burnham Institute For Medical Research | Compositions and Methods for Inhibiting Growth and Metastasis of Melanoma |
| CN102574890A (zh) * | 2010-08-23 | 2012-07-11 | 苏州润新生物科技有限公司 | 某些化学个体、组合物及方法 |
| WO2013177353A2 (en) * | 2012-05-25 | 2013-11-28 | S.P.M. Flow Control, Inc. | Apparatus and methods for evaluating systems associated with wellheads |
| CN104822374A (zh) * | 2012-09-27 | 2015-08-05 | 儿童医学中心公司 | 用于治疗肥胖症的化合物和其使用方法 |
| WO2015148802A1 (en) * | 2014-03-26 | 2015-10-01 | The Children's Medical Center Corporation | Celastrol and derivatives for the treatment of obesity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US20030027786A1 (en) | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
| FR2875913A1 (fr) | 2004-09-29 | 2006-03-31 | Sea On Line Sa | Systeme d'alerte anti-collision installe a bord d'un vehicule marin et procede d'analyse anti-collision |
| ES2277568B1 (es) | 2005-12-30 | 2008-04-01 | Consejo Superior De Investigaciones Cientificas | Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. |
| BR112014029301A2 (pt) * | 2012-05-25 | 2017-07-25 | Berg Llc | métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta |
| MA45430A (fr) | 2015-10-23 | 2019-05-01 | Erx Pharmaceuticals Inc | Analogues de célastrol |
| JP7268879B2 (ja) | 2017-01-02 | 2023-05-08 | ガウス サージカル，インコーポレイテッド | 重複撮像を予測した手術アイテムの追跡 |
-
2016
- 2016-10-21 MA MA045430A patent/MA45430A/fr unknown
- 2016-10-21 AU AU2016342375A patent/AU2016342375B2/en active Active
- 2016-10-21 BR BR112018008103-5A patent/BR112018008103A2/pt not_active Application Discontinuation
- 2016-10-21 JP JP2018541085A patent/JP7034078B2/ja active Active
- 2016-10-21 WO PCT/US2016/058313 patent/WO2017070615A1/en not_active Ceased
- 2016-10-21 CN CN202411356905.2A patent/CN119241632A/zh active Pending
- 2016-10-21 US US15/771,077 patent/US10662218B2/en active Active
- 2016-10-21 EP EP16858395.3A patent/EP3364956A4/en active Pending
- 2016-10-21 CN CN201680076127.9A patent/CN108601751A/zh active Pending
-
2020
- 2020-04-15 US US16/849,554 patent/US11753436B2/en active Active
-
2021
- 2021-11-04 JP JP2021179997A patent/JP7339992B2/ja active Active
-
2022
- 2022-06-17 AU AU2022204238A patent/AU2022204238B2/en active Active
-
2023
- 2023-07-17 US US18/353,272 patent/US20240190911A1/en active Pending
- 2023-08-25 JP JP2023136867A patent/JP2023164877A/ja not_active Withdrawn
-
2024
- 2024-03-07 AU AU2024201504A patent/AU2024201504A1/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007117466A2 (en) * | 2006-03-31 | 2007-10-18 | Massachusetts Institute Of Technology | Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors |
| US20100240581A1 (en) * | 2006-11-13 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | Selective proteasome inhibitors for treating diabetes |
| US20110166216A1 (en) * | 2007-08-17 | 2011-07-07 | Burnham Institute For Medical Research | Compositions and Methods for Inhibiting Growth and Metastasis of Melanoma |
| CN102574890A (zh) * | 2010-08-23 | 2012-07-11 | 苏州润新生物科技有限公司 | 某些化学个体、组合物及方法 |
| WO2013177353A2 (en) * | 2012-05-25 | 2013-11-28 | S.P.M. Flow Control, Inc. | Apparatus and methods for evaluating systems associated with wellheads |
| CN104822374A (zh) * | 2012-09-27 | 2015-08-05 | 儿童医学中心公司 | 用于治疗肥胖症的化合物和其使用方法 |
| WO2015148802A1 (en) * | 2014-03-26 | 2015-10-01 | The Children's Medical Center Corporation | Celastrol and derivatives for the treatment of obesity |
Non-Patent Citations (3)
| Title |
|---|
| CAS REGISTRY: "1361057-85-3", 《CAS REGISTRY》 * |
| LEE ET AL.: "The effect of celastrol on metabolic disturbances and renal injury in high fat diet-induced obesity mice", 《THE KOREAN JOURNAL OF NEPHROLOGY》 * |
| 郑月: "雷公藤红素对肝脏胰岛素抵抗的改善作用及机制研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109705187A (zh) * | 2019-01-29 | 2019-05-03 | 石家庄学院 | 一种雷公藤红素衍生物及其制备方法与应用 |
| CN112094313A (zh) * | 2019-06-17 | 2020-12-18 | 中国科学院上海药物研究所 | 一类氨基取代的雷公藤红素衍生物以及其制备方法和用途 |
| CN112094313B (zh) * | 2019-06-17 | 2023-07-04 | 中国科学院上海药物研究所 | 一类氨基取代的雷公藤红素衍生物以及其制备方法和用途 |
| CN112110977A (zh) * | 2019-06-21 | 2020-12-22 | 中国科学院上海药物研究所 | 一类雷公藤红素衍生物、其制备方法及用途 |
| WO2020253814A1 (zh) * | 2019-06-21 | 2020-12-24 | 中国科学院上海药物研究所 | 一类雷公藤红素衍生物、其制备方法及用途 |
| CN112110977B (zh) * | 2019-06-21 | 2022-02-25 | 中国科学院上海药物研究所 | 一类雷公藤红素衍生物、其制备方法及用途 |
| CN111202737A (zh) * | 2020-03-20 | 2020-05-29 | 中国药科大学 | 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用 |
| CN111202737B (zh) * | 2020-03-20 | 2022-08-05 | 中国药科大学 | 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用 |
| CN115677812A (zh) * | 2022-01-18 | 2023-02-03 | 聊城大学 | 一类雷公藤红素衍生物及其制备方法与应用 |
| CN115677812B (zh) * | 2022-01-18 | 2023-12-15 | 聊城大学 | 一类雷公藤红素衍生物及其制备方法与应用 |
| CN119431489A (zh) * | 2024-11-13 | 2025-02-14 | 肇源县总医院 | 一种雷公藤红素衍生物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7034078B2 (ja) | 2022-03-11 |
| AU2022204238B2 (en) | 2023-12-14 |
| AU2022204238A1 (en) | 2022-07-07 |
| JP2023164877A (ja) | 2023-11-14 |
| US20180362575A1 (en) | 2018-12-20 |
| AU2016342375A1 (en) | 2018-05-17 |
| RU2018118633A3 (enExample) | 2020-02-17 |
| AU2016342375B2 (en) | 2022-03-17 |
| EP3364956A4 (en) | 2019-05-01 |
| US20210061851A1 (en) | 2021-03-04 |
| US11753436B2 (en) | 2023-09-12 |
| WO2017070615A1 (en) | 2017-04-27 |
| JP7339992B2 (ja) | 2023-09-06 |
| MA45430A (fr) | 2019-05-01 |
| CA3002924A1 (en) | 2017-04-27 |
| BR112018008103A2 (pt) | 2018-11-06 |
| RU2018118633A (ru) | 2019-11-25 |
| JP2022017473A (ja) | 2022-01-25 |
| CN119241632A (zh) | 2025-01-03 |
| US20240190911A1 (en) | 2024-06-13 |
| US10662218B2 (en) | 2020-05-26 |
| AU2024201504A1 (en) | 2024-03-28 |
| EP3364956A1 (en) | 2018-08-29 |
| JP2018531289A (ja) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108601751A (zh) | 雷公藤红素的类似物 | |
| JP2018531289A6 (ja) | セラストロールの類似体 | |
| EP3681862B1 (en) | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | |
| JP5698682B2 (ja) | トライアシル−３−ヒドロキシフェニルアデノシン及びその血中脂肪の調節用途 | |
| TW201734012A (zh) | 經取代２－苯基－３－（哌甲基）咪唑并吡啶類及其用途 | |
| TW201919638A (zh) | 二氮雜雙環經取代之咪唑并嘧啶類及其用途 | |
| WO2020177587A1 (zh) | 治疗脂肪性肝病和/或脂肪性肝炎的方法 | |
| EA023751B1 (ru) | Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности | |
| KR20170124566A (ko) | 체지방 과다의 치료적 또는 미용적 치료를 위한 nk-3 수용체 길항제 | |
| WO2023105035A1 (en) | Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2 | |
| WO2019053429A1 (en) | CHIRAL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCEMIA | |
| US20250092086A1 (en) | Celastrol salts, crystalline forms, and uses thereof | |
| CN114075123B (zh) | 苄胺类衍生物及其制备方法与用途 | |
| RU2776845C2 (ru) | Аналоги целастрола | |
| JP2024515597A (ja) | ムスカリン性アセチルコリンｍ１受容体アンタゴニストの結晶性化合物 | |
| CN110267661A (zh) | 包括trh类似物和丙基辛酸的组合的组合物和丙基辛酸的药学上可接受的盐 | |
| US20240226069A1 (en) | Vafidemstat for use in treating autism spectrum disorders | |
| CA3002924C (en) | Analogs of celastrol | |
| JPS5955829A (ja) | 脳内の器質性障害に起因する精神機能症状の改善・治療剤 | |
| US20130012464A1 (en) | Glycyrrhizinates of morphinan derivatives | |
| BR122023014342B1 (pt) | Compostos análogos de celastrol, composição farmacêutica compreendendo ditos compostos e usos dos mesmos para tratar obesidade ou uma doença ou distúrbio relacionado à obesidade | |
| WO2005016331A1 (ja) | Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤 | |
| JP2025529076A (ja) | ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤 | |
| JPH0228113A (ja) | 高尿酸血症改善・治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180928 |